- Poster presentation
- Open Access
Gadofosveset trisodium in coronary magnetic resonance angiography at 3 Tesla
Journal of Cardiovascular Magnetic Resonance volume 16, Article number: P158 (2014)
Coronary magnetic resonance angiography (MRA) at 3T suffers from imaging inconsistencies compared to 1.5T despite the use of gadolinium-based contrast agents (GBCAs). Gadofosveset Trisodium (Ablavar®, Lantheus Medical Imaging), with its high relaxivity and long intravascular residence time, offers greater potential over standard GBCAs to improve evaluation of the coronary arteries. Compared to its validation in larger arteries, the optimum dosage for coronary MRA has yet to be assessed. The purpose of the study was to evaluate the diagnostic potential of a 0.06 mmol/kg dose of Gadofosveset compared to a standard clinical dose of 0.03 mmol/kg, using a free-breathing whole-heart coronary MRA protocol with 1.0 mm3 spatial resolution and 100% navigator efficiency. The injection protocol was optimized for the prolonged pharmacokinetics of Gadofosveset.
Twenty two contrast enhanced CMR scans were performed in 11 subjects [2 (18.2%) male; 27.3 ± 6 years; BMI = 23.1 ± 3 kg/m2] on a 3.0T Verio Siemens scanner, using an inversion-prepared spoiled gradient-echo sequence (modified from Ref. ). The two scans were separated by a 30-60 day interval, using dosages of either 0.06 mmol/kg or 0.03 mmol/kg of Gadofosveset. Quantitatively, signal-to-noise ratio (SNR) and contrast-to-noise ratios (CNR) were measured. Qualitative AHA quality scores were evaluated . Pairwise, Student's t-test and Wilcoxon rank test were performed for quantitative and qualitative assessment (MedCalc Software v12.2.1, MariaKerke, Belgium).
Overall, SNR and CNR was higher (p < 0.001) in the coronary arteries for double- over single-dose of Gadofosveset (24.18 ± 9.67 vs. 14.40 ± 5.0 and 14.27 ± 9.40 vs. 8.52 ± 4.01, respectively, Figure 1). Individual coronary arteries demonstrated greater SNR enhancement for 0.06 mmol/kg vs. 0.03 mmol/kg for the LMS (23.03 ± 7.45 vs. 12.37 ± 3.91, p < 0.001), LAD (26.12 ± 9.86 vs. 15.20 ± 3.88, p = 0.001), and RCA (29.54 ± 11.64 vs. 18.13 ± 6.29, p = 0.01). CNR comparisons revealed similar results. Qualitatively, similar number of main and branch vessels were identified by two reviewers (Figure 2).
Quantitatively, a double dose of Gadofosveset shows improvement in coronary arterial enhancement over clinical dose. Ongoing research is aimed at evaluating the diagnostic efficacy of a double-dose scanning regimen.
Funded by the National Institutes of Health (NIH) Intramural program.
Pang J, Bhat H, Sharif B: Whole-heart coronary MRA with 100% respiratory gating efficiency: Self-navigated three-dimensional retrospective imagebased motion correction (TRIM). Magn Reson Med. doi: 10.1002/mrm.24628
Scanlon PJ, Faxon DP, Audet AM: ACC/AHA guidelines for coronary angiography: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography) developed in collaboration with the Society for Cardiac Angiography and Interventions. Circulation. 1999, 99: 2345-2357.
About this article
Cite this article
Raman, F.S., Ahlman, M.A., Pang, J. et al. Gadofosveset trisodium in coronary magnetic resonance angiography at 3 Tesla. J Cardiovasc Magn Reson 16, P158 (2014). https://doi.org/10.1186/1532-429X-16-S1-P158
- Magnetic Resonance Angiography
- Wilcoxon Rank Test
- Coronary Magnetic Resonance Angiography
- Siemens Scanner
- Gadofosveset Trisodium